Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-04-04

AUTHORS

Chulhan Kim, Hyun Hoon Chung, So Won Oh, Keon Wook Kang, June-Key Chung, Dong Soo Lee

ABSTRACT

PurposeBorderline ovarian tumors (BOTs) are more common in young women of reproductive age, and exhibit a better prognosis than malignant ovarian tumors (MOTs). Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were compared in their ability to differentiate BOTs from stage I MOTs.MethodsAmong 173 patients who had preoperative FDG PET/CT due to ovarian neoplasms between November 2006 and March 2009, there were 13 patients with BOTs or stage I MOTs. For differential diagnosis of the two tumors, cancer antigen-125 (CA-125) level, the longest diameter of tumors, metabolic indices including maximum standardized uptake value (SUVmax), and volumetric indices including metabolic tumor volume (MTV) were compared, respectively.ResultsThe BOT group (n = 7) was comprised of five mucinous and two serous tumors, and the MOT group (n = 6) was comprised of three endometrioid, two clear cell and one mucinous tumors. Among the comparisons between two groups, SUVmax of the BOT group was significantly lower than that of the MOT group (2.9 ± 1.5 vs. 6.6 ± 2.9, p = 0.0223); otherwise, no significant difference was found in age, CA-125, diameter, or MTV. By receiver-operating characteristic curve analysis, SUVmax of 3.7 was the best cutoff value to differentiate BOTs from stage I MOTs, with a sensitivity of 83.3 % and specificity of 85.7, and the area under curve of 0.893 (p = 0.0001, 95 % CI: 0.601∼0.993).ConclusionsWe demonstrated that SUVmax could distinguish BOTs from stage I MOTs, with a high sensitivity and specificity. Metabolic indices determined by FDG PET/CT were more suitable than volumetric indices for differential diagnosis of the two tumors. More... »

PAGES

81-88

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13139-013-0197-5

DOI

http://dx.doi.org/10.1007/s13139-013-0197-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1024461458

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24900087


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, Korea University Ansan Hospital, Ansan, Korea", 
          "id": "http://www.grid.ac/institutes/grid.411134.2", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea", 
            "Department of Nuclear Medicine, Korea University Ansan Hospital, Ansan, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Chulhan", 
        "id": "sg:person.0641612406.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641612406.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chung", 
        "givenName": "Hyun Hoon", 
        "id": "sg:person.01170553552.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170553552.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, Seoul National University Boramae Medical Center, 20 Boramae-Ro-5-Gil, Dongjak-Gu, 156-707, Seoul, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.412479.d", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea", 
            "Department of Nuclear Medicine, Seoul National University Boramae Medical Center, 20 Boramae-Ro-5-Gil, Dongjak-Gu, 156-707, Seoul, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oh", 
        "givenName": "So Won", 
        "id": "sg:person.01166567043.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166567043.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kang", 
        "givenName": "Keon Wook", 
        "id": "sg:person.0761746266.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761746266.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chung", 
        "givenName": "June-Key", 
        "id": "sg:person.0751347234.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751347234.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Molecular Medicine and Biopharmaceutical Sciences, WCU Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea", 
            "Department of Molecular Medicine and Biopharmaceutical Sciences, WCU Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Dong Soo", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13139-010-0062-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029216225", 
          "https://doi.org/10.1007/s13139-010-0062-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-006-0260-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003841533", 
          "https://doi.org/10.1007/s00259-006-0260-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-005-1771-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037080992", 
          "https://doi.org/10.1007/s00259-005-1771-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-001-0750-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006601848", 
          "https://doi.org/10.1007/s00259-001-0750-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-04-04", 
    "datePublishedReg": "2013-04-04", 
    "description": "PurposeBorderline ovarian tumors (BOTs) are more common in young women of reproductive age, and exhibit a better prognosis than malignant ovarian tumors (MOTs). Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were compared in their ability to differentiate BOTs from stage I MOTs.MethodsAmong 173 patients who had preoperative FDG PET/CT due to ovarian neoplasms between November 2006 and March 2009, there were 13 patients with BOTs or stage I MOTs. For differential diagnosis of the two tumors, cancer antigen-125 (CA-125) level, the longest diameter of tumors, metabolic indices including maximum standardized uptake value (SUVmax), and volumetric indices including metabolic tumor volume (MTV) were compared, respectively.ResultsThe BOT group (n\u2009=\u20097) was comprised of five mucinous and two serous tumors, and the MOT group (n\u2009=\u20096) was comprised of three endometrioid, two clear cell and one mucinous tumors. Among the comparisons between two groups, SUVmax of the BOT group was significantly lower than that of the MOT group (2.9\u2009\u00b1\u20091.5 vs. 6.6\u2009\u00b1\u20092.9, p\u2009=\u20090.0223); otherwise, no significant difference was found in age, CA-125, diameter, or MTV. By receiver-operating characteristic curve analysis, SUVmax of 3.7 was the best cutoff value to differentiate BOTs from stage I MOTs, with a sensitivity of 83.3\u00a0% and specificity of 85.7, and the area under curve of 0.893 (p\u2009=\u20090.0001, 95\u00a0% CI: 0.601\u223c0.993).ConclusionsWe demonstrated that SUVmax could distinguish BOTs from stage I MOTs, with a high sensitivity and specificity. Metabolic indices determined by FDG PET/CT were more suitable than volumetric indices for differential diagnosis of the two tumors.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13139-013-0197-5", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1016285", 
        "issn": [
          "1869-3474", 
          "1869-3482"
        ], 
        "name": "Nuclear Medicine and Molecular Imaging", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "47"
      }
    ], 
    "keywords": [
      "malignant ovarian tumors", 
      "FDG PET/CT", 
      "metabolic tumor volume", 
      "PET/CT", 
      "ovarian tumors", 
      "differential diagnosis", 
      "MOT group", 
      "metabolic indices", 
      "preoperative FDG-PET/CT", 
      "fluorodeoxyglucose positron emission tomography/", 
      "cancer antigen 125 levels", 
      "receiver-operating characteristic curve analysis", 
      "positron emission tomography/", 
      "maximum standardized uptake value", 
      "antigen 125 levels", 
      "borderline ovarian tumors", 
      "emission tomography/", 
      "BOT group", 
      "best cutoff value", 
      "standardized uptake value", 
      "characteristic curve analysis", 
      "better prognosis", 
      "ovarian neoplasms", 
      "mucinous tumors", 
      "serous tumors", 
      "CA 125", 
      "volumetric indices", 
      "tomography/", 
      "reproductive age", 
      "clear cells", 
      "tumor volume", 
      "uptake value", 
      "cutoff value", 
      "tumors", 
      "longest diameter", 
      "young women", 
      "SUVmax", 
      "curve analysis", 
      "diagnosis", 
      "CT", 
      "significant differences", 
      "patients", 
      "age", 
      "group", 
      "index", 
      "endometrioid", 
      "prognosis", 
      "neoplasms", 
      "specificity", 
      "women", 
      "tomography", 
      "ConclusionsWe", 
      "sensitivity", 
      "cells", 
      "high sensitivity", 
      "levels", 
      "differences", 
      "diameter", 
      "volume", 
      "ability", 
      "values", 
      "curves", 
      "comparison", 
      "analysis", 
      "area", 
      "bots"
    ], 
    "name": "Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT", 
    "pagination": "81-88", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1024461458"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13139-013-0197-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24900087"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13139-013-0197-5", 
      "https://app.dimensions.ai/details/publication/pub.1024461458"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:39", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_616.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13139-013-0197-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13139-013-0197-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13139-013-0197-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13139-013-0197-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13139-013-0197-5'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      21 PREDICATES      95 URIs      83 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13139-013-0197-5 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nbfa98ee5398e42bf8cc9ce4cc0732f10
4 schema:citation sg:pub.10.1007/s00259-001-0750-9
5 sg:pub.10.1007/s00259-005-1771-6
6 sg:pub.10.1007/s00259-006-0260-x
7 sg:pub.10.1007/s13139-010-0062-8
8 schema:datePublished 2013-04-04
9 schema:datePublishedReg 2013-04-04
10 schema:description PurposeBorderline ovarian tumors (BOTs) are more common in young women of reproductive age, and exhibit a better prognosis than malignant ovarian tumors (MOTs). Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were compared in their ability to differentiate BOTs from stage I MOTs.MethodsAmong 173 patients who had preoperative FDG PET/CT due to ovarian neoplasms between November 2006 and March 2009, there were 13 patients with BOTs or stage I MOTs. For differential diagnosis of the two tumors, cancer antigen-125 (CA-125) level, the longest diameter of tumors, metabolic indices including maximum standardized uptake value (SUVmax), and volumetric indices including metabolic tumor volume (MTV) were compared, respectively.ResultsThe BOT group (n = 7) was comprised of five mucinous and two serous tumors, and the MOT group (n = 6) was comprised of three endometrioid, two clear cell and one mucinous tumors. Among the comparisons between two groups, SUVmax of the BOT group was significantly lower than that of the MOT group (2.9 ± 1.5 vs. 6.6 ± 2.9, p = 0.0223); otherwise, no significant difference was found in age, CA-125, diameter, or MTV. By receiver-operating characteristic curve analysis, SUVmax of 3.7 was the best cutoff value to differentiate BOTs from stage I MOTs, with a sensitivity of 83.3 % and specificity of 85.7, and the area under curve of 0.893 (p = 0.0001, 95 % CI: 0.601∼0.993).ConclusionsWe demonstrated that SUVmax could distinguish BOTs from stage I MOTs, with a high sensitivity and specificity. Metabolic indices determined by FDG PET/CT were more suitable than volumetric indices for differential diagnosis of the two tumors.
11 schema:genre article
12 schema:isAccessibleForFree true
13 schema:isPartOf N6c188e09b1c84a45a56b4aef9a2a7d42
14 N92e88aa5135648ad80b813faf028ad80
15 sg:journal.1016285
16 schema:keywords BOT group
17 CA 125
18 CT
19 ConclusionsWe
20 FDG PET/CT
21 MOT group
22 PET/CT
23 SUVmax
24 ability
25 age
26 analysis
27 antigen 125 levels
28 area
29 best cutoff value
30 better prognosis
31 borderline ovarian tumors
32 bots
33 cancer antigen 125 levels
34 cells
35 characteristic curve analysis
36 clear cells
37 comparison
38 curve analysis
39 curves
40 cutoff value
41 diagnosis
42 diameter
43 differences
44 differential diagnosis
45 emission tomography/
46 endometrioid
47 fluorodeoxyglucose positron emission tomography/
48 group
49 high sensitivity
50 index
51 levels
52 longest diameter
53 malignant ovarian tumors
54 maximum standardized uptake value
55 metabolic indices
56 metabolic tumor volume
57 mucinous tumors
58 neoplasms
59 ovarian neoplasms
60 ovarian tumors
61 patients
62 positron emission tomography/
63 preoperative FDG-PET/CT
64 prognosis
65 receiver-operating characteristic curve analysis
66 reproductive age
67 sensitivity
68 serous tumors
69 significant differences
70 specificity
71 standardized uptake value
72 tomography
73 tomography/
74 tumor volume
75 tumors
76 uptake value
77 values
78 volume
79 volumetric indices
80 women
81 young women
82 schema:name Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT
83 schema:pagination 81-88
84 schema:productId N4ccf35da80914a2e93d9dfda324619ff
85 N631025f07d154b74b5ce8458a4223433
86 Ncda2089725914a1c99370405db20ea64
87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024461458
88 https://doi.org/10.1007/s13139-013-0197-5
89 schema:sdDatePublished 2022-10-01T06:39
90 schema:sdLicense https://scigraph.springernature.com/explorer/license/
91 schema:sdPublisher N16261d0513f84c8d8d1ab08d15570653
92 schema:url https://doi.org/10.1007/s13139-013-0197-5
93 sgo:license sg:explorer/license/
94 sgo:sdDataset articles
95 rdf:type schema:ScholarlyArticle
96 N16261d0513f84c8d8d1ab08d15570653 schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 N2034a639f0064432b8faa9c2e7f18898 rdf:first N74d8a8c398fc47cbabcad95a02613c6b
99 rdf:rest rdf:nil
100 N28574dc69da64160ad21a2894b015de8 rdf:first sg:person.0761746266.86
101 rdf:rest N77cf9cb12c2c469b9c1d4b732e268370
102 N4ccf35da80914a2e93d9dfda324619ff schema:name dimensions_id
103 schema:value pub.1024461458
104 rdf:type schema:PropertyValue
105 N5b850c3ba30d4862b8d750fc56337803 rdf:first sg:person.01166567043.03
106 rdf:rest N28574dc69da64160ad21a2894b015de8
107 N631025f07d154b74b5ce8458a4223433 schema:name pubmed_id
108 schema:value 24900087
109 rdf:type schema:PropertyValue
110 N6c188e09b1c84a45a56b4aef9a2a7d42 schema:issueNumber 2
111 rdf:type schema:PublicationIssue
112 N74d8a8c398fc47cbabcad95a02613c6b schema:affiliation grid-institutes:grid.31501.36
113 schema:familyName Lee
114 schema:givenName Dong Soo
115 rdf:type schema:Person
116 N77cf9cb12c2c469b9c1d4b732e268370 rdf:first sg:person.0751347234.39
117 rdf:rest N2034a639f0064432b8faa9c2e7f18898
118 N92e88aa5135648ad80b813faf028ad80 schema:volumeNumber 47
119 rdf:type schema:PublicationVolume
120 Nbfa98ee5398e42bf8cc9ce4cc0732f10 rdf:first sg:person.0641612406.92
121 rdf:rest Nfa4ab62955134eab9e794ccf9505569a
122 Ncda2089725914a1c99370405db20ea64 schema:name doi
123 schema:value 10.1007/s13139-013-0197-5
124 rdf:type schema:PropertyValue
125 Nfa4ab62955134eab9e794ccf9505569a rdf:first sg:person.01170553552.32
126 rdf:rest N5b850c3ba30d4862b8d750fc56337803
127 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
128 schema:name Medical and Health Sciences
129 rdf:type schema:DefinedTerm
130 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
131 schema:name Clinical Sciences
132 rdf:type schema:DefinedTerm
133 sg:journal.1016285 schema:issn 1869-3474
134 1869-3482
135 schema:name Nuclear Medicine and Molecular Imaging
136 schema:publisher Springer Nature
137 rdf:type schema:Periodical
138 sg:person.01166567043.03 schema:affiliation grid-institutes:grid.412479.d
139 schema:familyName Oh
140 schema:givenName So Won
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166567043.03
142 rdf:type schema:Person
143 sg:person.01170553552.32 schema:affiliation grid-institutes:grid.31501.36
144 schema:familyName Chung
145 schema:givenName Hyun Hoon
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170553552.32
147 rdf:type schema:Person
148 sg:person.0641612406.92 schema:affiliation grid-institutes:grid.411134.2
149 schema:familyName Kim
150 schema:givenName Chulhan
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641612406.92
152 rdf:type schema:Person
153 sg:person.0751347234.39 schema:affiliation grid-institutes:grid.31501.36
154 schema:familyName Chung
155 schema:givenName June-Key
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751347234.39
157 rdf:type schema:Person
158 sg:person.0761746266.86 schema:affiliation grid-institutes:grid.31501.36
159 schema:familyName Kang
160 schema:givenName Keon Wook
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761746266.86
162 rdf:type schema:Person
163 sg:pub.10.1007/s00259-001-0750-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006601848
164 https://doi.org/10.1007/s00259-001-0750-9
165 rdf:type schema:CreativeWork
166 sg:pub.10.1007/s00259-005-1771-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037080992
167 https://doi.org/10.1007/s00259-005-1771-6
168 rdf:type schema:CreativeWork
169 sg:pub.10.1007/s00259-006-0260-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003841533
170 https://doi.org/10.1007/s00259-006-0260-x
171 rdf:type schema:CreativeWork
172 sg:pub.10.1007/s13139-010-0062-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029216225
173 https://doi.org/10.1007/s13139-010-0062-8
174 rdf:type schema:CreativeWork
175 grid-institutes:grid.31501.36 schema:alternateName Department of Molecular Medicine and Biopharmaceutical Sciences, WCU Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea
176 Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
177 Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
178 schema:name Department of Molecular Medicine and Biopharmaceutical Sciences, WCU Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea
179 Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
180 Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
181 rdf:type schema:Organization
182 grid-institutes:grid.411134.2 schema:alternateName Department of Nuclear Medicine, Korea University Ansan Hospital, Ansan, Korea
183 schema:name Department of Nuclear Medicine, Korea University Ansan Hospital, Ansan, Korea
184 Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
185 rdf:type schema:Organization
186 grid-institutes:grid.412479.d schema:alternateName Department of Nuclear Medicine, Seoul National University Boramae Medical Center, 20 Boramae-Ro-5-Gil, Dongjak-Gu, 156-707, Seoul, Seoul, Republic of Korea
187 schema:name Department of Nuclear Medicine, Seoul National University Boramae Medical Center, 20 Boramae-Ro-5-Gil, Dongjak-Gu, 156-707, Seoul, Seoul, Republic of Korea
188 Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...